Boosting Innovation for NTDs

Partnership objective

Undertake research on new treatments for NTDs, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness.

Partnerships and collaborations can play a crucial role in solving intractable challenges and tackling neglected diseases. Partnerships and collaborations can play a crucial role in solving intractable challenges and tackling neglected diseases. Copyright IFPMA

What are the health needs and challenges?

NTDs are a group of tropical infections that disproportionately affect the world’s poor and marginalized populations. According to the World Health Organization, more than a billion people or one-seventh of the global population suffer from one or more tropical infectious diseases.

Description of partnership activities and how they address needs and challenges

Since 2009, AbbVie has provided compounds for DNDi to screen for activity against neglected diseases. Currently, AbbVie is working with DNDi to follow up on screening hits for parasites causing visceral leishmaniasis and Chagas’ disease, and nematodes causing river blindness and lymphatic filariasis. Promising compounds are entered into the AbbVie-DNDi collaboration agreement the provides DNDi a non-exclusive license to relevant AbbVie IP for use in the neglected diseases field. Any resulting products will be provided in endemic countries at the lowest sustainable price to expand patient access.  AbbVie scientists also provide technical expertise to DNDi and participate as team members in DNDi discovery groups.

AbbVie also has a partnership with the Liverpool School of Tropical Medicine (LSTM) to help discover new macrofilaricides acting through an anti-Wolbachia mechanism. AbbVie is conducting the chemistry, DMPK, formulation and safety studies, and LSTM is conducting the in vitro anti-Wolbachia and animal efficacy screening.

Abbvie also partners with the University of Notre Dame to eliminate lymphatic filariasis (elephantiasis) in Haiti through salt fortification, mass drug administration and research.

MAP International is another partnership which aims to address Buruli ulcer in Cote D'Ivoire, providing AbbVie Foundation grants to educate and train health care professionals and schoolteachers in disease detection and management, and support health clinics that provide treatment and care.

Partnership information

Company(ies) AbbVie

Partner(s) Drugs for Neglected Diseases initiative (DNDi), Liverpool School of Tropical Medicine

Type of Partner(s) Academia / Hospitals, PDPs

Therapeutic Focus Neglected Tropical Diseases

Disease(s) Chagas Disease, Human African Trypanosomiasis (Sleeping Sickness), Leishmaniasis, Lymphatic Filariasis, Soil-Transmitted Helminthiasis

Program Type(s) Availability of Treatment - Technology Transfer - Scientific Collaboration and Knowledge Sharing, Research & Development - Development of Treatments

Targeted Population(s) Children, Elderly, Men, Mothers, People with low income, Women, Youth

Region(s) Latin America & Caribbean, Middle East & North Africa, South Asia, Sub-Saharan Africa

Number of Countries 35

Country(ies) Afghanistan, Angola, Argentina, Bangladesh, Benin, Bolivia, Botswana, Brazil, Burkina Faso, Cameroon, Central African Republic, Chad, Côte d'Ivoire, Democratic Republic of the Congo, Egypt, Gabon, Ghana, Guinea, India, Iran, Kenya, Malawi, Mali, Mexico, Mozambique, Nepal, Nigeria, Peru, Sudan, Syria, Tanzania, Togo, Uganda, Zambia, Zimbabwe

Research Country(ies) United States of America

Start Date 2009

More information AbbVie Website

Anticipated completion date Ongoing